May 23,2022

Sleepio Is the First-Ever Digital Therapeutic to Receive NICE Guidance, Confirming Clinical and Cost Effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds a new era in digital medicine.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Pear Presents Interim Real-World Data Showing Significant Reductions In Symptoms Of Chronic Insomnia, Anxiety And Depression With Somryst® At Sleep 2022

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced interim follow-up real-world data from DREAM, a remote, decentralized trial, that showed treatment with Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and six months later. Interim data from the DREAM study (NCT04325464), a remote, virtual, open-label, decentralized clinical trial evaluating Somryst, analyzed in mid-Q1 2022, included 993 adult patients (22-75 years of age) enrolled to date with chronic insomnia living in the U.S. who had access to a mobile device. As part of its PearCreate™ platform, Pear has developed its own remote, decentralized, virtual clinical trial infrastructure for participant recruitment, screening, consent, enrollment, follow up, and progress tracking, which was used for the DREAM study.

CLINICAL STUDY

#pdt

#rwe

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 02,2022

ResMed Acquires Digital Therapeutics App for Insomnia

Today ResMed, a provider of digital health solutions for sleep and respiratory care, acquires Germany-based mementor, the maker of somnio, which provides a digital solution for treating insomnia and marks ResMed’s first foray into the digital therapeutics space. Through the acquisition, mementor can leverage ResMed Germany’s broader network to increase adoption of its approved digital therapy alternative for insomnia; somnio is available today in Germany via “app on prescription.”

COLLABORATION MERGERS & ACQUISITION

#product & service

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 10,2022

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia severity for Somryst® (previously known as SHUTi in its prior incarnation), the only FDA-authorized PDT for the treatment of chronic insomnia. The analysis evaluated real-world data of 248 adult patients with chronic insomnia treated with Somryst over 24-months compared to the 24-months months prior to treatment and found: Reductions in health-related services; An estimated $2,059 reduction in per-patient costs; 37.2% reduction in mean insomnia severity index (ISI) score (19.1 at baseline and 12.0 at nine weeks).

CLINICAL STUDY

#pdt

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Study Demonstrates Combining Digital Therapeutics for Insomnia and IAPT Therapy Improves Sleep, Anxiety, and Depression More Than Therapy Alone

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, and the Oxford Health NHS Foundation Trust today announced a joint study published in the Behaviour Research and Therapy journal showing almost two-thirds [65 percent] of people seeking treatment for anxiety or depression and who had sleep difficulty saw their mental health improve substantially more by combining enrollment in Sleepio, Big Health’s digital therapeutic for insomnia, with NHS Improving Access to Psychological Therapies programme (IAPT) care, when compared to IAPT care alone.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Sep 06,2021

NHS Sleepio project in North Hampshire shortlisted for award

NHS bosses in North Hampshire have been shortlisted a prestigious award for its "groundbreaking" project. North Hampshire Clinical Commissioning Group formed a partnership with Big Health to prescribe the cognitive behavioural therapy (CBT) app Sleepio for free for those with trouble sleeping. An alternative to prescribing drugs, the partnership has now been shortlisted in the mental health innovation category at the Health Service Journal awards. Big Health UK director Dr Charlotte Lee added: “We are proud of our partnership with the NHS in North Hampshire to provide non-drug alternatives for mental health.''

PRODUCT

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 23,2021

Pear Therapeutics Announces Additional Coverage Decisions And Formulary Adoption Of Its Prescription Digital Therapeutics

Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today updated the number of entities providing coverage for its three commercial products, reSET®, reSET-O®, and Somryst®. With these new coverage decisions, there are now more than 30 organizations that are providing access to Pear’s PDTs by either listing on formulary, as a covered benefit, or purchasing products in bulk.

PRODUCT

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 23,2021

Pear Therapeutics and Serve You Rx Announce Formulary Coverage For Prescription Digital Therapeutic Somryst

Pear Therapeutics, Inc. and Serve You Rx announced today that Somryst®, the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia, will be added to Serve You Rx’s formularies and be administered as a standard pharmacy benefit for its members, effective July 1, 2021. Somryst, intended for use in the treatment of patients 22 years of age and older with chronic insomnia, addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), an evidence-based approach that trains the brain and body to sleep.

COLLABORATION PARTNERSHIP

#insurance

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Scotland offers access to Big Health's DTx for anxiety, insomnia

Scotland is making a cognitive behavioral therapy app for anxiety and insomnia available to all adults in the country, marking a major validation of digital therapeutics to treat behavioral health conditions. Scotland's National Health Service (NHS) will offer national access to products from digital therapeutic maker Big Health at no cost to the user. About 5 million people will be eligible for access to Sleepio, the company’s app to treat insomnia with cognitive behavioral therapy, and Daylight, which is focused on combating worry and anxiety.

PRODUCT

#reimbursement

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 17,2021

Review: We test new sleep and anxiety therapies being offered on the NHS in Scotland

A review on the user experience for the Sleepio and Daylight solutions from Big Health is provided, after the move by the Scottish Government to make the programmes available on the NHS.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to INSOMNIA